加载中
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
前收盘价
US$31.00
+US$0.92 · +3.06%
盘中时间采用ET。市场数据可能有所延迟。
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
日内区间
当前US$31.00
52周区间
当前US$31.00
盘中时间采用ET。市场数据可能有所延迟。
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
日内区间
当前US$31.00
52周区间
当前US$31.00
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 461.9万 USD | — | — | — | — |
| 毛利 | −461.9万 USD | — | — | — | — |
| 研究与开发 | 2.7亿 USD | 2.33亿 USD | 1.74亿 USD | 1.22亿 USD | 5591.3万 USD |
| 销售、一般及管理费用 | 6358.3万 USD | 4328.1万 USD | 3437.5万 USD | 2621.2万 USD | 1963.8万 USD |
| 营业费用 | 3.29亿 USD | 2.76亿 USD | 2.08亿 USD | 1.48亿 USD | 7555.1万 USD |
| 利息收入 | 1468.9万 USD | 1808.8万 USD | 1307.7万 USD | 398.9万 USD | 46.7万 USD |
| 利息支出 | 306.2万 USD | — | — | 398.9万 USD | — |
| 折旧和摊销 | 458.3万 USD | 435.1万 USD | 358.8万 USD | 587.8万 USD | 14.7万 USD |
| 营业利润 | −3.33亿 USD | −2.76亿 USD | −2.08亿 USD | −1.48亿 USD | −7555.1万 USD |
| 净利润 | −3.29亿 USD | −2.56亿 USD | −1.92亿 USD | −1.4亿 USD | −7227.3万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$51.75
上涨空间 66.94%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.81亿0.01%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1.32亿0.17%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB1.31亿0.07%1853亿 USD0.03%US$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI1.19亿1.20%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Morningstar Small-Cap Value ETFVBR8301.73万0.12%682亿 USD0.05%US$234.43+0.22%
Vanguard Extended Market ETFVXF6949.63万0.07%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO4632.92万0.34%139.17亿 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB3627.31万0.34%108.2亿 USD0.44%US$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
